NCT06549465: An ongoing trial by Convergent Therapeutics
This trial is ongoing. It must report results 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06549465 |
|---|---|
| Title | A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 6, 2024 |
| Completion date | Dec. 31, 2025 |
| Required reporting date | Dec. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |